Recent research indicates that while GLP-1 medications significantly reduce body weight, fat-free mass lost accounts for 25-40% of the total weight lost during therapy, raising concerns about muscle loss
It was initially approved by the Food and Drug Administration (FDA) in 2017 to manage blood sugar for people with Type 2 diabetes
Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, et al
For more details : #NovoNordisk #Semaglutide #Wegovy #Ozempic #HealthcareInnovation #MetabolicHealth #HeartHealth #BrainHealth #Biopharma #FutureOfMedicine To view or add a comment, sign in MetaVia (NASDAQ: MTVA) has announced positive, statistically significant results from the eight-week, non-titrated, 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), for the treatment of obesity
If your order does arrive warm, understanding what happens when semaglutide gets warm and how to assess potential degradation is critical
